当前位置：药药网 / 数据中心 /奥大利亚药品评审报告(本栏目收费,不能显示细节,电话13136136841)
药品名称：
活性成份：
发布日期：-
奥大利亚药品评审报告745个记录(本栏目收费,不能显示细节,电话13136136841)
奥大利亚药品评审报告
21
Glycophos
Sodium glycerophosphate (as hydrate)
2020/2/13
22
Cimzia
Certolizumab pegol (rbe)
2020/2/13
23
Calquence
Acalabrutinib
2020/2/17
24
Nucala
Mepolizumab
2020/2/18
25
Lorviqua
Lorlatinib
2020/2/21
26
Zavicefta
Ceftazidime/Avibactam
2020/2/24
27
Calquence
Acalabrutinib
2020/2/17
28
Talzenna
Talazoparib (as tosilate)
2020/2/25
29
Zirabev
Bevacizumab
2020/2/26
30
Zykadia
Ceritinib
2020/3/4
31
Increlex
Mecasermin
2020/3/5
32
Pifeltro and Delstrigo
Doravirine and doravirine/ lamivudine/ tenofovir disoproxil fumarate
2020/3/11
33
Takhzyro
Lanadelumab
2020/3/4
34
Ogivri
Trastuzumab
2020/3/18
35
Alunbrig
Brigatinib
2020/3/12
36
Adacel
Pertussis vaccine - acellular combined with diphtheria and tetanus toxoids (adsorbed)
2020/3/23
37
Opdivo
Nivolumab
2020/3/17
38
Oxervate
Cenegermin (rbe)
2019/11/26
39
Sonidegib
Odomzo
2019/11/27
40
INOmax
Nitric oxide
2019/11/28